GLP-1s and the sovereignty question

I spent a chunk of April reading research briefs on the GLP-1 class of drugs — semaglutide, tirzepatide, retatrutide, the new oral orforglipron that just got FDA approval. The numbers from the trials are striking. Tirzepatide produces ~20% weight loss. Retatrutide hit 28.7% in Phase 3, the highest figure ever published in an obesity trial. Wegovy HD, approved last month, gets 20.7% in plateau patients. These are not modest interventions. They are doing something to metabolic regulation that diet-and-exercise advice has never reproduced at scale.

The instinct, in the freedom-tech / biohacking / sovereignty world I run in, is to be skeptical of any pharmaceutical with that kind of efficacy curve. The skepticism is partly well-earned — there are real discontinuation rates (12-18% at the higher doses), real safety signals being monitored, real questions about long-term effects on muscle mass and metabolic adaptation. Those are worth tracking.

But the skepticism that isn’t well-earned is the kind that conflates “I want to be sovereign over my health” with “the answer must be a supplement stack from a podcast sponsor.” Sovereignty over your own metabolism doesn’t mean refusing the most effective tool because it came out of a pharmaceutical pipeline. It means understanding the tool — the mechanism, the trade-offs, the trial data, the discontinuation curves, what it does and doesn’t address — and making a decision that’s actually yours.

Health sovereignty, the way I’m starting to think about it, isn’t an ideological allergy to medicine. It’s the discipline of being the informed principal on your own body. That can mean GLP-1s. It can also mean rejecting them. What it can’t mean is outsourcing the question to the loudest voice in your tribe.

The other thing I keep coming back to: metabolic dysregulation at population scale is infrastructure rot. It’s the substrate everything else sits on. If a drug class can move that needle 20% — and the pipeline coming behind it (retatrutide, CagriSema, monthly injectables in the late 2020s) might move it 30% — that is a structural intervention, whether the sovereignty crowd wants to admit it or not.

I haven’t decided what I’d do for myself. I’m watching the data and the discontinuation rates and the long-term cohorts. But I’m not going to pretend the question is settled by ideology either way.

This is a personal observation, not medical advice. Talk to your doctor. Read the trial data. Make your own call.